Key Highlights
- Pharmaceutical giant AbbVie plans a $1.4 billion, 185-acre manufacturing facility in Durham, North Carolina
- Represents the company’s biggest-ever investment in a single manufacturing location
- Facility will focus on producing sterile injectable treatments for immunology, oncology and neuroscience conditions
- Project will generate 734 full-time positions within four years and over 2,000 temporary construction roles
- Development begins in 2026 with anticipated completion in late 2028
Pharmaceutical leader AbbVie revealed plans Wednesday for a $1.4 billion state-of-the-art manufacturing complex in Durham, North Carolina — marking the company’s most significant investment in a single facility to date.
The expansive 185-acre complex will be strategically positioned near the renowned Research Triangle Park, functioning as AbbVie’s primary U.S. hub for small volume parenteral (SVP) production. The facility will manufacture sterile injectable medications — including vials, pre-filled syringes and cartridges — designed to treat various conditions spanning immunology, neuroscience and oncology therapeutic areas.
This development marks AbbVie’s inaugural major manufacturing presence in the North Carolina region.
Development is scheduled to commence later in 2026, with full operational capability targeted for late 2028. The initial construction phase encompasses manufacturing facilities, research laboratories, warehouse infrastructure, administrative offices and employee wellness amenities.
The pharmaceutical company intends to recruit 734 permanent staff members throughout a four-year period — including engineers, research scientists, manufacturing technicians and laboratory specialists. Additionally, the construction phase will generate employment for more than 2,000 workers during the development timeline.
Chief Executive Officer Robert A. Michael stated the commitment “strengthens our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina.”
Component of $100 Billion Domestic Investment Strategy
The Durham manufacturing complex represents just one element of a significantly larger strategic initiative. AbbVie has committed approximately $100 billion toward U.S.-based research, development and manufacturing operations throughout the coming decade.
Within just the past year, the pharmaceutical manufacturer has allocated more than $2.2 billion to domestic manufacturing initiatives spanning North Carolina, Illinois, Arizona and Massachusetts.
Earlier in February, AbbVie unveiled a $380 million investment to construct two active pharmaceutical ingredient production facilities at its North Chicago, Illinois headquarters, dedicated to neuroscience and obesity therapeutic development.
The Durham campus strengthens that strategic expansion.
Strategic Location Selection
AbbVie selected the Research Triangle Park region due to its highly educated workforce and substantial capacity for future growth.
North Carolina Governor Josh Stein praised the announcement, describing the state as “the premier location for biopharmaceutical companies to do business.”
Once operational, the manufacturing complex will distribute medications to both U.S. and international markets, serving as a critical distribution center for AbbVie’s injectable pharmaceutical production nationwide.
AbbVie presently maintains approximately 29,000 employees throughout the United States, including over 6,000 staff at its domestic production facilities. Following this announcement, the company’s aggregate U.S. employment expansion over the previous year surpasses 1,300 new roles across four different states.
The facility will also incorporate artificial intelligence and cutting-edge manufacturing technologies throughout its operations — a strategic priority AbbVie emphasized in its public statement.
This initiative signifies AbbVie’s first establishment in North Carolina as a manufacturing base, and company officials indicate the location has been strategically planned to accommodate future pipeline expansion requirements.
